Serum CXCL13 and PECAM-1 can be used as diagnostic and prognostic markers in elderly patients with gastric cancer

Li, Y.; Guo, Xiaoping; Wei, Yanghui; Kang, Xiaoyu

doi:10.1007/s12094-020-02403-w

Cited by 10 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wei et al used immunohistochemistry to detect the expression of CXCL13 in gastric cancer tissues. Low CXCL13 expression was found to be associated with longer survival in stage T2-4 patients [ 31 ]. Lee et al studied the effect of Escin on the migration and invasion of AGS human gastric cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Characterization of the Prognostic Values of CXCL Family in Epstein–Barr Virus Associated Gastric Cancer

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Background. CXCL family is a class of secreted growth factors signaling through G-protein-coupled receptors, and abnormal expression is associated with the growth and progression of many tumors. However, their prognostic value has been poorly studied in Epstein–Barr virus- (EBV-) associated gastric cancer (EBVaGC). Therefore, it is of great significance to explore the prognostic value of the CXCL family in EBVaGC. Methods. CXCL family mRNA expression was analyzed in STAD data from The Cancer Genome Atlas (TCGA). Kaplan-Meier Plotter was used to assess the prognostic value of the CXCL family. Transcription factors (TFs) and miRNAs associated with the CXCL family were identified by TFCheckpoint, miRWalk, and ViRBase databases. The prognostic model was evaluated using the EBVaGC patient cohort GSE51575. Results. The mRNA expression of CXCL1/3/5/6/8/9/10/11/16 was significantly upregulated, while the expression of CXCL12/14 was downregulated in EBVaGC compared with normal tissues from TCGA-STAD. The mRNA expressions of CXCL9, CXCL10, CXCL11, and CXCL17 in EBVaGCs were higher than those in EBVnGCs, but the mRNA expressions of CXCL6, CXCL12, and CXCL17 were lower than those in EBVnGCs. The mRNA expression levels of CXCL9, CXCL10, and CXCL11 in EBVaGCs were higher than those in EBVnGCs regardless of the tumor stage. High mRNA expression of CXCL8 was associated with better OS in patients with EBVaGC, while high expression of CXCL9 was associated with better OS in patients with EBVnGC. We obtained 10 candidate potential transcription factors (TFs) associated with CXCLs: OTOP3, NKX6-2, NKX2-2, FEV, SMYD1, TRIMSO, TBX10, CDX1, SLC26A3, and ARC. 576 miRNA-mRNA interactions were obtained. Among them, 65 miRNAs were predicted to be correlated with CXCL6, CXCL9, CXCL10, and CXCL11. Similar to the results of TCGA-STAD, the GSE51575 dataset also showed that the mRNA expression levels of CXCL1/3/9/10/11/16 were markedly enhanced in EBVaGC tissues compared with corresponding normal gastric mucosa tissues, while the mRNA expression levels of CXCL12/14 were significantly reduced. The mRNA expression levels of CXCL3/9/10/11/13/17 were increased in EBVaGC compared with EBVnGC tissues. Conclusions. The expression differences of CXCL family members are closely associated with the progression of EBVaGC. Expression of CXCL9/10/11/17 mRNA may be a promising prognostic indicator for EBVaGC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of the Prognostic Values of CXCL Family in Epstein–Barr Virus Associated Gastric Cancer

et al. 2022

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…ERBB2 was replicated through elevated gene transcription in various of cancer cells, and tumor growth depended on ERBB2 amplification heavily ( 45 ). A series of studies identified that PECAM1 was linked to development of several malignances and had the potential to be a diagnostic and prognostic biomarker in gastric cancer patients ( 46 , 47 ). The knockdown of TIMP1 expression inhibited metastasis, and proliferation but prompted apoptosis of colon cancer through activating FAK-PI3K/AKT and MAPK pathway ( 48 ).…”

Section: Discussionmentioning

confidence: 99%

Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma

et al. 2023

View full text Add to dashboard Cite

BackgroundDespite progression in its treatment, the clinical outcome of patients with clear cell renal cell carcinoma (ccRCC) remains not ideal. Anoikis is a unique form of programmed apoptosis, owing to insufficient cell-matrix interactions. Anoikis plays a crucial role in tumor migration and invasion, and tumor cells could protect themselves through the capacity of anoikis resistance.MethodsAnoikis-related genes (ARGs) were obtained from Genecards and Harmonizome portals. The ARGs related to ccRCC prognosis were identified through univariate Cox regression analysis, then we utilized these ARGs to construct a novel prognostic model for ccRCC patients. Moreover, we explored the expression profile of ARGs in ccRCC using the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) database. We also conducted Real-Time Polymerase Chain Reaction (RT-PCR) to probe ARGs expression of the risk score. Finally, we performed correlation analysis between ARGs and tumor immune microenvironment.ResultsWe identified 17 ARGs associated with ccRCC survival, from which 7 genes were chosen to construct a prognostic model. The prognostic model was verified as an independent prognostic indicator. The expression of most ARGs was higher in ccRCC samples. These ARGs were closely correlated with immune cell infiltration and immune checkpoint members, and had independent prognostic value respectively. Functional enrichment analysis demonstrated that these ARGs were significantly associated with multiple types of malignances.ConclusionThe prognostic signature was identified to be highly efficient in predicting ccRCC prognosis, and these ARGs were closely related to tumor microenvironment.

show abstract

“…CD31 is often employed as an indicator of the extent of tumor invasion in cancer [ 29 ]. In gastric cancer, CD31 can be used as an indicator of survival related to angioinvasion [ 30 ]. In contrast to non-tumor conditions, higher HMGA1 expression has been correlated with lower expression of CD31 in a mouse model of pulmonary hypertension [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer

Chen

2022

Life

View full text Add to dashboard Cite

The prognosis of advanced gastric cancer remains poor. Overexpression of high mobility group A 1 (HMGA1) in breast cancer and neuroblastoma indicates a poor prognosis. However, the relationship between HMGA1 expression and gastric cancer development remains unclear. Treatment strategies can be developed by identifying potential markers associated with gastric cancer. We used a constructed tissue array and performed hematoxylin and eosin and immunohistochemical staining. We quantified the staining results and performed statistical analysis to evaluate the relationship between HMGA1 expression and prognosis. HMGA1 expression was related to the expression of Ki-67, caspase3, CD31, N-cadherin, fibronectin, pAkt, and pErk. In the Kaplan–Meier graph, higher HMGA1 expression levels were associated with a relatively poor survival rate (p = 0.04). High expression of HMGA1 leads to a low survival rate, which is associated with HMGA1, proliferation, apoptosis, angiogenesis, epithelial-mesenchymal transition, and tyrosine kinase.

show abstract

Serum CXCL13 and PECAM-1 can be used as diagnostic and prognostic markers in elderly patients with gastric cancer

Cited by 10 publications

References 26 publications

Characterization of the Prognostic Values of CXCL Family in Epstein–Barr Virus Associated Gastric Cancer

Characterization of the Prognostic Values of CXCL Family in Epstein–Barr Virus Associated Gastric Cancer

Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma

High Mobility Group A 1 Expression as a Poor Prognostic Marker Associated with Tumor Invasiveness in Gastric Cancer

Contact Info

Product

Resources

About